Depression and Relapsing-remitting multiple sclerosis

Summary:

Relapsing-remitting multiple sclerosis is found among people with Depression, especially for people who are female, 40-49 old.

The study analyzes which people have Relapsing-remitting multiple sclerosis with Depression. It is created by eHealthMe based on reports of 17 people who have Depression from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Depression?

Depression is found to be associated with 3,168 drugs and 4,126 conditions by eHealthMe. Check the latest studies of Depression.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

On Jul, 22, 2026

17 people who have Depression and Relapsing-Remitting Multiple Sclerosis are studied.

Would you have Relapsing-remitting multiple sclerosis when you have Depression?

Gender of people who have Depression and experienced Relapsing-Remitting Multiple Sclerosis *:

female: 94.12 %
male: 5.88 %

Age of people who have Depression and experienced Relapsing-Remitting Multiple Sclerosis *:

Common co-existing conditions for these people *:

Stress And Anxiety: 8 people, 47.06%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 29.41%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 3 people, 17.65%
Inflammation: 3 people, 17.65%
Pain: 2 people, 11.76%
Fatigue (feeling of tiredness): 2 people, 11.76%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 5.88%
Ill-Defined Disorder: 1 person, 5.88%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.88%
Eye Pain: 1 person, 5.88%

Common drugs taken by these people *:

Common symptoms for these people *:

Hypoaesthesia (reduced sense of touch or sensation): 8 people, 47.06%
Fatigue (feeling of tiredness): 7 people, 41.18%
Constipation: 6 people, 35.29%
Gait Disturbance: 6 people, 35.29%
Dizziness: 6 people, 35.29%
Insomnia (sleeplessness): 5 people, 29.41%
Weakness: 5 people, 29.41%
Balance Disorder: 4 people, 23.53%
Pain: 4 people, 23.53%
Rashes (redness): 4 people, 23.53%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Relapsing-remitting multiple sclerosis?

- Check whether Relapsing-remitting multiple sclerosis is associated with a drug or a condition

Related publications that referenced our studies

Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .
Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .

Related studies:

Treatments, associated drugs and conditions:

Depression (652,144 reports)
Relapsing-remitting multiple sclerosis (76,275 reports)

All the drugs that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (126 drugs)

All the conditions that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (178 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Relapsing-remitting multiple sclerosis and Depression, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.